E
Nirvana Life Sciences Inc. NIRV
CNSX
Recommendation
Prev Close
Volume
--
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)

10/31/2024 07/31/2024 04/30/2024 01/31/2024 10/31/2023
Net Income -9.29% 84.04% -6,507.50% 103.23% 54.18%
Total Depreciation and Amortization -- -- -50.00% -- --
Total Amortization of Deferred Charges -- -- -- -- --
Total Other Non-Cash Items 20,400.00% -100.07% 224.50% -422.49% -79.84%
Change in Net Operating Assets -91.54% -64.04% 24.64% 134.20% 58.26%
Cash from Operations -2,525.00% 81.40% 31.75% 87.86% 34.14%
Capital Expenditure -- -- -- -- --
Sale of Property, Plant, and Equipment -- -- -- -- --
Cash Acquisitions -- -- -- -- --
Divestitures -- -- -- -- --
Other Investing Activities -- -- -- -- --
Cash from Investing -- -- -- -- --
Total Debt Issued 609.43% 15.22% 130.00% -85.29% 70.00%
Total Debt Repaid -- -- -- -- 100.00%
Issuance of Common Stock -- -- -- -100.00% -86.49%
Repurchase of Common Stock -- -- -- -- --
Issuance of Preferred Stock -- -- -- -- --
Repurchase of Preferred Stock -- -- -- -- --
Total Dividends Paid -- -- -- -- --
Other Financing Activities -- -- -- -- 100.00%
Cash from Financing 626.32% 11.76% 126.67% -94.72% -71.74%
Foreign Exchange rate Adjustments -- -- -- -- --
Miscellaneous Cash Flow Adjustments -313.64% -- -- -- --
Net Change in Cash -412.50% 188.89% 81.25% 79.49% -207.83%
Weiss Ratings